PT  - JOURNAL ARTICLE
AU  - IWASA, SATORU
AU  - YAMADA, YASUHIDE
AU  - KATO, KEN
AU  - GOTO, AYUMU
AU  - HONMA, YOSHITAKA
AU  - HAMAGUCHI, TETSUYA
AU  - SHIMADA, YASUHIRO
TI  - Long-term Results of a Phase II Study of S-1 plus Irinotecan in Metastatic Colorectal Cancer
DP  - 2012 Sep 01
TA  - Anticancer Research
PG  - 4157--4161
VI  - 32
IP  - 9
4099  - http://ar.iiarjournals.org/content/32/9/4157.short
4100  - http://ar.iiarjournals.org/content/32/9/4157.full
SO  - Anticancer Res2012 Sep 01; 32
AB  - Aim: The current study aimed to assess the long-term efficacy of combination therapy with oral S-1, a fluoropyrimidine prodrug, plus irinotecan in previously untreated patients with metastatic colorectal cancer. Patients and Methods: Between April 2004 and February 2005, 41 patients with previously untreated advanced or recurrent colorectal cancer were enrolled in the study. Chemotherapy consisted of oral administration in S-1 at 40 mg/m2 twice daily on days 1 to 14 and intravenous infusion of irinotecan at 150 mg/m2 on day 1 in a 21-day cycle. Results: The median patient follow-up was 78.0 months. The median survival time was 23.7 months, and the 2-year survival rate was 50%. The median time to tumor progression was 8.3 months. Conclusion: The results of this long-term update confirmed that first-line combination therapy with oral S-1 plus irinotecan was effective in patients with metastatic colorectal cancer.